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ABBREVIATIONS 
CKD – chronic kidney disease 
CKD 5  -  chronic kidney disease stage 5 
CKD-5D  -  chronic kidney disease stage 5 on dialysis 
TB  -  tuberculosis 
HD  -  haemodialysis 
PD  -  peritoneal dialysis 
CAPD- continuous ambulatory peritoneal dialysis 
WHO  -  world health organization 
INH  -  isoniazid 
AFB  -  acid fast bacilli   
VBP- vitamin D binding protein 
25(OH)vitD3 – 25 hydroxyvitamin D3 
1,25(OH)2vitD3- 1,25 dihydroxyvitamin D3 
FGF-23 – fibroblast growth factor -23 
MTB- mycobacterium tuberculosis complex 
TST- Tuberculin skin test  
IGRA- interferon gamma release assay 
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PART A: Abstract 
Background 
Tuberculosis (TB) now ranks as the leading cause of death from a single infectious agent 
worldwide. Patients on dialysis are particularly vulnerable to TB infection due to immune 
dysfunction.  Despite this, there is a paucity of incidence data on TB in dialysis patients in high 
burden settings such as South Africa. The aim of this study was to determine the incidence of TB 
in chronic kidney disease stage 5 patients on dialysis (CKD-5D) at a single centre in the Eastern 
Cape, South Africa and to identify risk factors associated with TB infection.  
Methods 
We conducted a retrospective cohort study of all consenting prevalent CKD-5D patients between 
April 2010 and March 2014 at the Livingstone Tertiary Hospital Renal Unit in the Eastern Cape, 
South Africa.  TB was defined as “definite” or “probable” according to WHO criteria.   
Results 
One hundred and eleven patients were enrolled: they were predominantly black African (73%) 
and female (53%); mean age was 42 years (SD ±9years).  The prevalence of HIV infection was 
11%: all were on antiretroviral treatment and all had suppressed viral loads. Sixty eight patients 
were on haemodialysis (HD) and 43 patients were on peritoneal dialysis (PD).   Nineteen patients 
were diagnosed with 20 episodes of TB; 14 cases were pulmonary and 6 cases extrapulmonary.  
Of the patients with TB, 2 were HIV infected. Of the 20 TB cases, 7 (35%) were definite TB 
cases and 13 (65%) had probable TB.  The calculated incidence rate was 4505 per 100 000 
patient years. Only informal housing and a history of hospitalization were significant ly 
associated with a diagnosis of TB. 
Conclusion 
Dialysis patients in the Eastern Cape region of South Africa are at extremely high risk for the 
acquisition of TB with an incidence rate that is 4.1 times that of the local Nelson Mandela Bay 
population and over 5 times that reported in the general population for the country as a whole. 
Only informal housing and a history of hospitalization were identified as positive risk factors in 
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this young population with a low HIV prevalence. Isoniazid prophylaxis in this high risk group 
might be of benefit but further studies are required to inform such treatment. 
PART B: Structured Literature review 
WORD COUNT 3494 
a. Introduction and worldwide epidemiology of tuberculosis  
Tuberculosis remains a major health burden and is now the leading cause of death from an 
infectious agent worldwide
1
 .  In 2017, the world health organization reported an estimated 10.0 
million new TB cases worldwide, of which 5.8 million cases were among men, 3.2million cases 
among women and 1.0 million cases among children
1
. People living with HIV accounted for 9% 
of all new TB cases
1
. The estimated number of TB deaths in 2017 was 1.3 million among HIV 
negative people, and an additional 300 000 deaths resulting from TB disease among people 
living with HIV
1
. Although deaths from TB are still unacceptably high, it has been reported that 
the number of TB deaths is declining every year with an estimated fall of TB deaths by 29% 
among HIV negative patients and 44% among HIV positive patients between year 2000 and 
2017
1
.  
South Africa has an estimated tuberculosis incidence of 567 per 100 000 population
1
. The 
Eastern Cape Provincial Department of Health has reported cure rates of 77% which is below the 
targeted 90% recommended by the WHO
2
. The South African national treatment cure rates vary 
between 62% and 82% depending on whether it’s a new case or a retreatment case1.  
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b. Incidence and clinical presentation of tuberculosis in CKD patients on 
dialysis 
The incidence of tuberculosis is higher in dialysis patients with a reported incidence of active TB 
among prevalent dialysis patients of 6.9 to 52.5 times higher than the general population  
depending on regional factors
3,4,5,6
.High income countries report a lower incidence than that 
mentioned above but the incidence of TB is still increased in dialysis patients compared to the 
general population and also carries a high mortality
7
. Dobler et al, in a large population based 
cohort study involving 19.9 million Australians reported that people on dialysis have a seven to 
eight-fold increased risk of developing TB compared with the general population ,the overall 
incidence of TB among patients on dialysis was 66.8 per 100,000 person-years compared to the 
incidence of TB of 5.7 per 100,000 in the general population over their study period
5
. 
The incidence and prevalence of TB in dialysis patients in sub Saharan Africa is largely 
undocumented. However, one study from Limpopo, South Africa reviewed the outcomes of 
CAPD patients who developed tuberculous peritonitis and reported that TB peritonitis carries a 
high mortality rate in patients on CAPD even when they are treated for the infection
8
. Their 
cohort had a 7.1% of diagnosed and treated cases of TB peritonitis
8
. 
The increased incidence of tuberculosis in dialysis patients is thought to be a result of impaired 
cell mediated immunity
6
.The uremic state of CKD-5 is associated with granulocyte and 
lymphocyte dysfunction and this is particularly significant for the development of tuberculosis as 
granulocytes and lymphocytes are the cells responsible for killing intracellular organisms like 
mycobacterium tuberculosis
9
.  
The diagnosis of TB among dialysis patients can be challenging because the presentation is often 
insidious and patients present with non-specific symptoms including malaise, fever, weight loss 
and adenopathy
10
. Extra pulmonary TB is more common in patients with CKD-5 and caseating 
necrosis is often absent owing to their immunosuppressed state
10
. The diagnosis of TB in CKD-
5D therefore requires a very index of suspicion and tissue biopsies and cultures are frequently 
required to make the diagnosis. This non-specific symptomatology and difficulty in ascertaining 
13 
 
drug sensitivity contributes to the delay in diagnosis and initiation of effective treatment
3
. 
Tamayo-Isla et al. recently emphasized the difficulties encountered with making the diagnosis of 
TB in CAPD patients, and that a combination of biochemical, microbiological and radiological 
assessments need to be employed to prove the diagnosis
8
. In their cohort, TB was isolated in only 
9/12 (75%) of the patients and the diagnosis of TB in the other 25% was made based on chest 
radiograph and abdominal ultrasound features suggestive of TB
8
. Vikrant also reiterated the 
difficulty with making a definite diagnosis of TB in dialysis patients and only 50% were 
confirmed cases in his cohort and the other 50% was treated based on clinical grounds
11
. 
c. Risk factors for tuberculosis in dialysis patients 
Risk factors for TB in the general population include: host related risk factors including 
conditions which cause immunosuppression-HIV, diabetes and use of immunosuppressive 
drugs,
12
 plus environmental and socioeconomic related risk factors such as overcrowded 
households, use of biomass fuel and poor ventilation
12
. Health care workers are also at increased 
risk of TB because of occupational exposure to TB patients
12
.  
 Risk factors for development of TB in dialysis patients can be divided into modifiable and non-
modifiable risk factors. The non-modifiable risk factors include advanced age, primary cause of 
chronic kidney disease (such as diabetic nephropathy) and ethnicity
13
. These non-dialysis related 
risk factors are themselves associated with depressed cell mediated immunity and anergy of 
effector lymphocytes thereby increasing risk of TB infection, and further serve as confounding 
factors to the high incidence of tuberculosis in CKD
7,13
.  
Modifiable risk factors include, malnutrition, smoking and the mode of dialysis
7
. Haemodialysis 
patients are at increased risk of TB compared to PD patients
7
. The frequent hospital visits, lack 
of isolation facilities and close proximity of patients to each other during the dialysis sessions are 
thought to contribute to this increased risk
7
. Klote et al. showed in their study that age (p<0.001), 
haemodialysis (vs peritoneal dialysis, p=0.019), unemployment (p<0.001), reduced BMI 
(p<0.001), ischaemic heart disease (p=0.032), smoking history (p=0.010), illicit drug use 
(p=0.018), reduced serum albumin (p<0.001), and African American (p=0.001) and Asian 
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(p=0.002) race were independently statistically significant risk factors for the development TB 
infection
7
. 
HIV as a modifiable risk factor is particularly significant, and poses a great challenge for our 
CKD population in the African context given that Sub-Saharan Africa already has a huge burden 
of the HIV and TB co-epidemic.  A significant number of the TB cases are diagnosed within the 
first year of starting dialysis
14
 and Unsal et al., reported that in their retrospective review 54.2% 
of their TB cases were diagnosed in their first year of dialysis
14
. This may be because of the 
general poor state of health and seriously impaired immune host defense mechanism  at the start 
of their dialysis treatment
14
.   
d. Effect of chronic kidney disease on the immune system 
The key function of the immune system includes detecting and destroying invading microbes
15
. 
The immune defense against invading microbes is accomplished through a complex interaction 
between the innate and adaptive immune system
15
. The innate immune system comprises of cells 
and processes that culminate in a non-specific and rapid response to invading microorganisms. 
The innate immune system  includes circulating monocytes and their tissue counterparts, 
macrophages, neutrophilic polymorphonuclear leukocytes, dendritic cells, natural killer cells, 
mast cells, eosinophils, basophils, and nearly all other cells in the body
15
.  The adaptive immune 
system on the other hand has a more complicated well developed capacity for host defense and 
plays a role in the host recognizing and remembering specific pathogens and enables the host to 
mount stronger attacks on re-encounter with the same pathogen
16
 . The adaptive immune system 
includes T and B lymphocytes which express cell specific receptors with which they recognize 
specific antigens
16
. 
While immune dysfunction in CKD is complex and not fully understood, a number of 
mechanisms have been suggested including: (a)decreased granulocyte and 
monocyte/macrophage phagocytic function, (b) defective antigen-presenting capacity of antigen-
presenting cells, (c) depletion of the antigen-presenting dendritic cells, (d) reduced numbers and 
antibody producing capacity of B cells, (e) increased T cell turnover and apoptosis leading to 
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depletion of naive and central memory CD 41 and CD81 T cells and impaired cell-mediated 
immunity
15
. 
 
e. Immunopathogenesis and classification of TB disease 
TB is a communicable infectious disease caused by the mycobacterium tuberculosis (MTB) 
complex and is transmitted via droplet spread through person to person contact
17
. After 
inhalation the MTB complex is taken up by dendritic cells and alveolar macrophages where it 
proliferates and sets off an intracellular signaling cascade resulting in the production of various 
cytokines
18
.  MTB complex then gets transported by dendritic cells to mediastinal lymph nodes 
where antigen presenting cells activate T cells resulting in activation of adaptive immune 
response and production of more cytokines resulting in the formation of an immune granuloma 
comprised of macrophages, neutrophils, monocytes, dendritic cells, and T cells
18
. 
Tuberculosis can be classified according to the anatomical site of the disease as either pulmonary 
or extra-pulmonary TB
19
. Pulmonary TB refers to TB disease involving the lung parenchyma. 
Included in this category are miliary TB, tuberculous hilar lymphadenopathy and pleural effusion 
with lung parenchymal changes. Extra-pulmonary TB includes TB in the following sites,  pleura, 
lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges
20
. Extra-pulmonary 
TB accounts for 15-20% of TB in populations with low HIV prevalence,
19
 but in high HIV 
prevalence areas, the proportion of cases is much higher
19
. 
Tuberculosis can also be classified bacteriologically as either ‘smear positive’ or ‘smear 
negative’. A patient is considered smear positive when one or more initial sputum smear 
examinations by direct smear microscopy is AFB- positive, or one sputum examination is AFB-
positive in association with radiographic abnormalities consistent with active pulmonary TB as 
determined by a clinician or one sputum sample positive for AFBs and culture positive for 
AFBs
20
. Smear-positive cases are the most infectious
19
. 
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Smear negative TB includes at least two sputum AFB-negative smear examinations but with one 
or more of the following: a positive culture result, radiographic abnormalities consistent with 
active pulmonary TB, histologic evidence of caseating granulomas or no response to a course of 
broad-spectrum antibiotics  plus a decision by a clinician to treat with a full course of anti-TB 
chemotherapy
19
.  
Table 1: WHO Tuberculosis clinical classification
1,21
 
Case classification Definition  
Definite TB
1
 A patient with mycobacterium TB identified on a clinical 
specimen either by culture or new molecular line probe assay 
specimens. For countries which lack facilities to routinely identify 
mycobacterium TB, one or more initial sputum samples positive 
for acid fast bacilli (AFB) is considered definite TB case, 
provided there is a functional external quality assurance protocol 
for blind rechecking. 
 
   
Probable TB
21
 Any patient who does not fit the ‘definite’ TB case defined above 
but has clinical symptoms including one/more of the following: 
1. Cough more than two weeks plus other respiratory 
symptoms (shortness of breath, chest pain, haemoptysis) 
2. Constitutional symptoms such as loss of weight, loss of 
appetite, drenching night sweats. 
PLUS one or more of: 
1. Radiological abnormalities consistent with TB. 
2. Histology of biopsy tissue showing caseating granulomas. 
3. No response to broad spectrum antibiotics and a decision 
by a clinician to treat with a full course of anti-TB 
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therapy. 
   
No TB TB disease has been activity excluded. 
f. Latent TB infection in dialysis patients 
Getahun et al. define latent TB infection as a state of persistent bacterial viability, immune 
control without evidence of clinically manifested active tuberculosis
22
. An estimated 2 billion 
people worldwide have latent TB and are at risk of reactivation
23
. The annual rate of reactivation 
of latent TB in South Africa is estimated at 4.2%
22
. CKD-5 confers an increased risk of 
reactivation of latent TB because of immune dysfunction
22
. The risk of reactivation of latent TB 
infection is 10-25 times higher in CKD-5 patients compared to the general population
24
,
25
. There 
are two tests currently used for screening for latent TB infection. Tuberculin skin test (TST) 
which uses PPD (purified protein derivative) containing many antigens and the antigen specific  
interferon gamma release assays (IGRA’s) that detect the release of interferon γ by T cells in 
response to tuberculosis specific antigens. The usefulness of tuberculin skin testing in assessing 
latent tuberculosis infection in dialysis patients is questionable because of very low sensitivity
26
 
with false negatives of up to 50% due to impaired host immune response and anergy have been 
reported
27
. False positives are not infrequent because of the cross reactivity of TST with Bacillus 
Calmette–Guérin (BCG) antigens, especially in countries where BCG is part of the national 
immunization programme.  However the effect of BCG on the results of TST is expected to not 
last more than 15 years and the induration of the TST as a result of BCG immunization should 
not be more than 15mm
28
.  The usefulness of TST in areas where TB is endemic is therefore 
questionable. The new IGRA can be used together with the tuberculin skin test to screen for 
latent tuberculosis infection. The IGRA tests serve to complement and not substitute TST and 
results in increased sensitivity for detecting latent TB infection
29
.  
The current recommendations in low tuberculosis incidence areas are to screen only selected 
patients within a dialysis programme such as those who are on the transplant waiting list, young 
patients with a long life expectancy and those who have immigrated from tuberculosis endemic 
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areas
27
.  Screening of all patients in these areas is not recommended as it may not be cost 
effective and the risk of hepatitis from chemoprophylaxis may outweigh that of development of 
tuberculosis
27
. 
The above recommendations may not necessary be applicable to tuberculosis endemic areas. One 
randomized clinical trial done in India demonstrated significant protection against development 
of tuberculosis with Isoniazid (INH) prophylaxis given for a period of 1 year to CKD-5D 
patients.  INH has been found to be reasonably safe and well tolerated
30,31
.  Although there may 
be concerns of emergence of drug resistant TB with use of INH prophylaxis, a recent South 
African cohort study done in a high TB prevalence area showed that active tuberculosis infection 
following recent isoniazid prophylaxis had treatment outcomes and prevalence of drug resistance 
similar to that of the general population
30
. 
There are currently no guidelines in South Africa to inform us on INH prophylaxis in dialysis 
patients. The only widely available data on INH chemoprophylaxis is for HIV infected patients
32
. 
A recent published trial in South African gold mine workers showed no reduction in either the 
incidence or prevalence of tuberculosis or the rate of death from any cause after 9 months of INH 
chemoprophylaxis at 18 months follow up.  Although the incidence of TB was reduced during 
chemoprophylaxis, protection from infection was rapidly lost on discontinuation of INH
33
.  
Tuberculosis tends to behave as an opportunistic infection in transplant patients and the current 
recommendations
34
 from the European Best Practice Guidelines for Renal Transplantation
35
 and 
the American Society of Transplantation
36
 are for a 9-month course of INH prophylaxis. A meta-
analysis by Currie A.C et al recommends prophylaxis in renal transplant recipients in endemic 
areas or in recipients in non-endemic countries who are at risk including immigrants from TB 
endemic countries
34
. 
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g. Vitamin D metabolism and deficiency in TB 
According to current international guidelines, vitamin D deficiency can be defined as a 25-
hydroxyvitamin D level of <30nmol/L and insufficiency as 30-75nmol/L
37
.  CKD5 is associated 
with low levels of vitamin D as a result of deficiency of 25 hydroxyvitamin D3 as well as 
impaired hydroxylation of 25 hydroxyvitaminD3 to the active metabolite 1, 25 dihydroxyvitamin 
D3 by the enzyme 1 alpha hydroxylase in the kidneys and elsewhere in the body
38
.  A number of 
mechanisms in which CKD 5 results in vitamin D deficiency have been suggested, including the 
loss of functional renal mass leading to decreased production of 1 alpha hydroxylase
39
. Other 
suggested mechanisms including suppression of enzyme activity due to metabolic acidosis, 
hyperphosphatemia, and accumulation of other uraemic toxins associated with CKD have been 
suggested
39
. In addition to the mechanisms stated above, one other main physiological regulator 
of vitamin D metabolism in CKD is fibroblast growth factor-23 (FGF-23)
39
.  
 In the pre antibiotic era, vitamin D was used in the treatment of tuberculosis
40
. Vitamin D 
facilitates monocyte-macrophage activity in the body and plays a role in human innate immunity 
to certain infectious agents
41
. This role is thought to be important in the body’s defense against 
tuberculosis. Vitamin D acts by binding to nuclear receptors in target cells. Therefore, both 
abnormalities in vitamin D receptor structure and function and low serum levels of vitamin D 
may result in impairment in hosts handling of the tubercle bacillus
41
. First, the active form of 
vitamin D enhances the ability of macrophages to suppress the intracellular growth of 
Mycobacterium tuberculosis
41,42
. Secondly, on triggering of toll-like receptors by molecules of 
the TB bacillus, production of microbiocidal cathelicidin is impaired in the absence of adequate 
serum vitamin D
41,42
.  
Several studies assessing the association of active tuberculosis and vitamin D status have been 
done
41
 with most reporting an increased prevalence of vitamin D deficiency in tuberculosis
43
.  
The highest prevalence of vitamin D deficiency in an African study was reported in a South 
African study done on HIV infected and HIV uninfected black patients  in Cape Town, which 
showed a prevalence of 62,7% as defined by a 25-Hydroxyvitamin D level of <50 nmol/L
44
. One 
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study done in prevalent dialysis patients in Cape Town revealed a combined prevalence of 
vitamin D insufficiency/deficiency of 57%
45
.   
Studies have shown an increased risk of TB in patients with vitamin D deficiency.  Therefore, 
patients with advanced kidney disease may have a compounded risk of TB as a result of their 
depressed cellular immunity in conjunction with vitamin D deficiency.   
Although observational studies have shown an  association between vitamin D deficiency and 
increased prevalence of tuberculosis, randomized controlled studies have demonstrated 
conflicting results with most studies to date failing to show any benefit from vitamin D 
supplementation to non-CKD TB patients 
40
.  
h. TB in Renal Transplant patients 
Renal transplant recipients are reported to be at an increased risk of TB infection owing to their 
immunosuppressed state. Reis-Santos et al in their meta-analysis, reported an increased 
combined TB prevalence rate of 2.51% which is 14 times greater than the prevalence rate of 
0.18% seen in the general population
46
. 
i. Treatment of TB in CKD and transplantation 
The pharmacodynamics of antituberculosis drugs determine how their levels are likely to be 
influenced by renal failure, clearance during dialysis and also their interaction with 
immunosuppressive drugs used in patients undergoing renal transplantation
47
. The British 
Thoracic Society recommends for active TB cases with CKD to be treated with 4 drugs( with 
drug dosage modifications)  in the first 2 months followed by 2 drugs for a further 4 months with 
the exception of central nervous infections which requires a prolonged treatment duration of up 
to 12 months
47
. No drug dose adjustments are required for isoniazid and rifampicin as both drugs 
are extensively metabolized by the liver
48
. Pyrazinamide dosages need to be adjusted as it 
accumulates and it’s thought to interfere with uric acid metabolism with resultant hyperuricaemia 
and increased risk for gout arthropathy
48
. Its dosage adjustment is as shown in Table 2
47
. 
Ethambutol and aminoglycosides are renal eliminated and thus require dose adjustments to avoid 
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toxicity as shown in Table 2
47
. If a major concern for ethambutol toxicity exists, then ethambutol 
can be substituted with moxifloxacin during the first 2 months of the initiation phase. For 
patients on haemodialysis the drugs can be given immediately post dialysis or alternatively 4-6 
hours before dialysis to avoid premature drug elimination
47
. It is advisable to monitor peak and 
trough levels of drugs including ethambutol and aminoglycosides where possible to avoid under 
and over dosing
47
. 
In transplant patients anti-TB drug interactions with immunosuppressive treatment poses a major 
challenge and can lead to acute graft rejection
47
. Rifampicin is the drug most likely to interfere 
with immunosuppressive therapy as it is a strong inducer of multiple enzyme systems and many 
drug adjustments need to made including doubling the dose corticosteroids and ciclosporin drug 
levels need to be closely monitored and dose adjusts employed accordingly
47
.  
 
 
Table 2 : British Thoracic Society’s recommended doses of first line drugs in CKD47 
 Stage 1-3 CKD Stage 4 and 5 CKD Renal transplant 
recipients 
Isoniazid 300mg daily 300mg daily or 
15mg/kg maximum 
900mg 3*/week 
300mg daily 
Rifampicin <50kg :450mg daily <50kg :450mg daily <50kg :450mg daily 
≥50kg :600mg daily ≥50kg : 600mg daily ≥50kg :600mg daily 
Pyrazinamide <50kg :1.5g daily 25-30mg/kg 3*week <50kg :1.5g daily 
≥50kg :2.5g daily ≥50kg :2g daily 
Ethambutol 15mg/kg daily 15-25mg/kg 3*weekly 
maximum(2.5g) 
15mg/kg daily 
Moxifloxacin 400mg daily Not suitable for 
3*weekly regimen 
400mg daily 
j. Relevance and rationale of the study 
Tuberculosis still remains an important cause of morbidity and mortality despite employed 
strategies to improve diagnosis and treatment success rates
1
. The burden of tuberculosis is 
reportedly higher in CKD-5D patients owing to impaired cell mediated immunity
6
.  
22 
 
Given that there is limited published data regarding the burden of tuberculosis in CKD-5D 
patients in South Africa and that the real extent of the problem is therefore unknown, we sought 
to highlight the burden of tuberculosis and identify any modifiable risk factors that can be 
addressed in the CKD-5D population. 
On completion of the study we hope to make recommendations that will inform and ultimately 
improve the care of end stage kidney disease patients in the Eastern Cape. 
k. Study objectives 
Primary Objective 
1. To determine the incidence of TB in the Livingstone renal unit patients with CKD-5D 
over the study period. 
Secondary objectives 
1. To identify variables associated with an increased risk for TB in CKD-5D. 
2. To compare vitamin D deficiency in the dialysis patients diagnosed with tuberculosis 
with those who do not develop TB. 
3. To compare the incidence of TB in Livingstone Hospital CKD-5D patients with the 
Eastern Cape Province as a whole. 
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WORD COUNT 1897 
Abstract 
Background 
Tuberculosis (TB) now ranks as the leading cause of death from a single infectious agent 
worldwide. Patients on dialysis are particularly vulnerable to TB infection due to immune 
dysfunction.  Despite this, there is a paucity of incidence data on TB from dialysis patients in 
high burden settings.  
Objective  
To determine the incidence of TB in chronic kidney disease stage 5 patients on dialysis (CKD-
5D) at a single centre in the Eastern Cape, South Africa and to identify risk factors associated 
with TB infection. 
Methods 
We conducted a retrospective cohort study of all consenting prevalent CKD-5D patients between 
April 2010 and March 2014 at the Livingstone Tertiary Hospital Renal Unit in the Eastern Cape, 
South Africa.  TB was defined as “definite” or “probable” according to WHO criteria and the 
cohort was split into those who developed TB (TB+) and those that did not (TB-).   
Results 
One hundred and eleven patients were enrolled: they were predominantly black African (73%) 
and female (53%); mean age was 42 years (SD ± 9years).  The prevalence of HIV infection was 
11%: all were on antiretroviral treatment and all had suppressed viral loads. Sixty eight patients 
were on haemodialysis (HD) and 43 patients were on peritoneal dialysis (PD).   Nineteen patients 
were diagnosed with 20 episodes of TB; 14 cases were pulmonary and 6 cases extrapulmonary.  
Of the patients with TB, 2 were HIV infected. Of the 20 TB cases, 7 (35%) were definite TB 
cases and 13 (65%) had probable TB.  The calculated incidence rate was 4505 per 100 000 
patient years. Only informal housing (30% in TB+ versus 12% in TB-, p = 0.042) and a history 
of hospitalization (90% versus 76% respectively, p = 0.042) were significantly associated with a 
diagnosis of TB. 
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Conclusion 
Dialysis patients in the Eastern Cape region of South Africa are at extremely high risk for the 
acquisition of TB with an incidence rate that is 4.1 times that of the local Nelson Mandela Bay 
population and over 5 times that reported in the general population for the country as a whole. 
Only informal housing and a history of hospitalization were identified as positive risk factors in 
this young population with a low HIV prevalence. Isoniazid prophylaxis in this high risk group 
might be of benefit but further studies are required to inform such treatment. 
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a. Introduction 
Tuberculosis (TB) remains a major global health burden, responsible for ill health among 
millions of people each year and now ranks as the leading cause of death from a single infectious 
agent worldwide
 [1]
. South Africa has a reported TB incidence of 567 cases per 100 000/year
 [1]
. 
The reported incidence of TB in the Nelson Mandela Bay district, Eastern Cape Province, South 
Africa is 1009 per 100 000/year
[2]
, much higher than the national average where it is  reported to 
be the leading cause of death in ages 25-64 years
[2]
. Unfortunately, South Africa is still failing at 
a national level to reach the proposed target of 90% treatment cure rate as set by the World 
Health Organization, and currently sits at 82%
[1]
.  
Patients on dialysis are particularly vulnerable to active mycobacterium TB infection (hereafter 
referred to as TB) compared to the general population due to immune dysfunction induced by the 
uraemic state
[3,4,5]
. In other lower middle income countries (LMIC) , the incidence of TB among 
prevalent dialysis patients is reported to be 6.9 to 52.5 times higher than it is in the general 
population, depending on regional factors and background prevalence
[6,7,8]
. Despite this, there is 
a paucity of epidemiological and incidence data on TB from dialysis patients in South Africa. 
We are only aware of one published single-centre study by Tamayo-Isla et al. conducted in 
Polokwane, Limpopo Province wherein they describe a high mortality associated with TB 
peritonitis in CAPD patients
[9]
.     
b. Objective  
To determine the incidence of TB in chronic kidney disease stage 5 patients on dialysis (CKD-
5D) at a single centre in the Eastern Cape, South Africa and to identify modifiable and non-
modifiable risk factors associated with TB.  
c. METHODS 
d. Study design and ethics approval 
The study was approved by the Research Ethics Committee of the University of Cape Town 
(HREC/REF 127:2014), South Africa and permission was obtained from local authorities. We 
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conducted a retrospective cohort study of all consenting prevalent CKD-5D patients between 
April 2010 and March 2014 in the Livingstone Hospital Renal Unit, Eastern Cape Province, 
South Africa. A total of 111 consenting prevalent dialysis patients were enrolled in the study.  
 
e. Data collection 
 
 TB was defined as “definite” or “probable” according to WHO criteria[11]. Definite TB cases 
were defined as cases where mycobacterium tuberculosis complex was identified from a clinical 
specimen either by culture or newer methods, including line probe assays. Probable TB cases 
were those cases with constitutional symptoms, radiological features suggestive of  TB and 
caseating granulomas on histological tissue, but with no positive culture identification of 
mycobacterium TB
[11]
.  A medical questionnaire with all the required data was used. Patient 
demographics including dialysis vintage, age, gender, race (self-reported), employment status, 
smoking, alcohol use, history of hospitalization during the study period but prior to enrollment, 
housing type and TB household contact status were recorded. Details concerning the diagnosis of 
tuberculosis, mean time between initiation of dialysis and diagnosis of TB, HIV status, Vitamin 
D level, comorbidities and medications were also recorded.  
f. Statistical analysis 
The estimated incidence was calculated as a percentage of patients surveyed and then converted 
into an incidence per 100 000 divided by 4 (for the 4 years) to give an estimated incidence per 
100 000 per year of study period. 
Normality was determined with the Shapiro-Wilk test.Continuous variables were expressed as 
mean ± SD while categorical variables were presented as frequencies and percentages. 
Univariate analysis was performed using the independent student’s t-test, chi-squared test or the 
Wilcoxon rank sum test as appropriate.  All analyses were conducted using Stata 12.0 Statistical 
Software (College Station, TX, USA). 
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g. Results 
Baseline characteristics of the patients including gender, HIV status, prior immunosuppression 
use, employment, smoking, known TB contact status and dialysis modality are presented in 
Table 1.  One hundred and eleven patients were enrolled: they were predominantly Black 
African (73%) and female (53%); mean age was 42.1 (± 9.8) years.  The prevalence of HIV 
infection was 11%: all were on antiretroviral treatment.  Sixty eight patients were on 
haemodialysis (HD) and forty three patients were on peritoneal dialysis (PD); 93% of the 
patients were unemployed.   
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Table 1: Baseline characteristics assessed between the TB+ and TB- dialysis patients. .  Abbreviations: HD, 
haemodialysis; PD, peritoneal dialysis; TB, tuberculosis. 
Table 1:Baseline characteristics assessed between the TB+ and TB- dialysis patients.(N=111) 
Variables ALL (%) 
(n=111) 
 
TB+(%) 
(n=19) 
TB-(%) 
(n-92) 
P-value 
Variable Value TB+ TB- p-value 
Age, mean (years) 42 42.4 41.8 0.868 
Gender (%)     
    Female 53 45 55 0.396 
Employment Status (%)     
   Unemployed 93 90 93 0.584 
Smoking Status (%)     
   ≥10 Pack years 16 10 18 0.405 
   < 10 pack years 84 90 82 0.405 
Hospitalisation (%) 79 90 76 0.042 
Housing (%)     
   Brick 85 70 88 0.042 
  Shack 15 30 12 0.042 
Use of biomass fuel (%) 8 5 8.7 0.582 
TB contact (%) 28 40 25 0.174 
HIV status (%)     
   Positive 11 10 11 0.909 
Use of immunosuppression (%) 8 1.4 6.6 0.171 
Vitamin D (nmol/L) %     
(Deficiency and insufficiency) 45.7 20.8 79.2 0.800 
Dialysis modality     
HD 61 18 82 0.898 
PD 39 19 81 0.898 
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The spread of TB diagnosis is shown in Figure 1.   
Figure 1 : Site of TB diagnosis 
 
The characteristics of patients with TB are shown in table 2.  Nineteen patients (18%) were diagnosed 
with TB over the 4 year study period, with one patient treated for TB on two occasions (patient #6 and 7 
on table 2),giving a total of 20 TB cases; 14 cases were pulmonary, and 6 extrapulmonary as shown in 
figure 1. Of the 20 TB cases, 7 (35%) were definite TB cases and 13 (65%) had probable TB.  Of the 7 
definite cases: 1 (#5) had TB peritonitis with dialysate effluent culture positive for drug sensitive 
mycobacterium TB; 2 cases (#7 and 11) had TB adenitis and culture confirmed drug sensitive 
mycobacterium TB; 1 case (#1) had disseminated mycobacterium  TB with a miliary pattern on chest X 
ray,  a bone marrow biopsy that showed caseating granulomas and a mycolytic blood culture that 
confirmed a drug sensitive mycobacterium TB; 1 case (#9) had drug resistant mycobacterium TB(MDR) 
on culture; 1 case (#12) of pulmonary TB had positive acid fast bacilli on sputum microscopy but no 
culture was available and 1 case (#13) was pulmonary TB with a suggestive chest radiograph (CXR) and 
was positive for drug sensitive TB on sputum culture. 
Of the thirteen probable TB cases, 10 were diagnosed based on clinical features and lymphocytic pleural 
effusion, 2 had pericardial effusions with stranding on echocardiogram and a pericardial tap on both 
patients revealed a lymphocyte-predominant picture and 1 had a miliary pattern on CXR but negative 
culture. 
14 
1 
2 
2 
1 
TB Positive Cases 
Pulmonary TB
TB pericarditis
TB adenitis
TB peritonitis
Bone marrow
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Patient 
 
Gender 
 
Age 
(years) 
 
Race 
 
Cause of CKD 
 
Time on dialysis* 
(months) 
 
Housing 
 
HIV status 
 
Dialysis 
modality 
 
Location of TB 
Infection 
 
TB culture and 
smear results 
 
Definite/probable 
 
Drug 
sensitivity** 
 
1 Female 52 Black HPT 4 Brick Negative HD Bone marrow Positive Definite Sensitive 
2 Female 44 Black HPT 63 Shack Negative HD Pleural effusion Negative Probable Not available 
3 Female 39 Black Unknown 3 Brick Positive HD Pleural effusion Negative Probable Not available 
4 Female 35 Mixed HPT 0 Shack Negative PD Pleural effusion Negative Probable Not available 
5 Male 34 Black Chronic GN 16 Brick Negative PD Peritoneal fluid Positive Definite Sensitive 
6 Female 59 Black HPT 12 Brick Negative HD Pulmonary Negative Probable Not available 
7 Female 59 Black HPT 12 Brick Negative HD TB adenitis Positive Definite Sensitive 
8 Male 38 Black Unknown 56 Brick Positive HD Pleural effusion Negative Probable Not available 
9 Female 53 Black HPT 38 Shack Negative HD Pulmonary Positive Definite MDR TB 
10 Female 50 Mixed HPT 50 Brick Negative PD TB pericarditis Negative Probable Not available 
11 Male 34 Mixed Unknown 72 Brick Negative PD TB adenitis Positive Definite Sensitive 
12 Male 45 Black HPT 35 Brick Negative HD Pleural effusion AFB on smear Definite Not available 
13 Male 56 Black HPT 32 Shack Negative HD Pulmonary Positive Definite Sensitive 
14 Male 43 Black HPT 19 Brick Negative PD Pleural effusion Negative Probable Unknown 
15 Male 31 Black Chronic GN 2 Brick Negative PD TB pericarditis Negative Probable Unknown 
16 Male 28 Mixed HPT 13 Brick Negative PD Milliary Negative Probable Unknown 
17 Female 41 Mixed Chronic VUR 44 Brick Negative HD Pleural effusion Negative Probable Unknown 
18 Male 35 Black Unknown 37 Shack Negative HD Pleural effusion Negative Probable Unknown 
19 Male 38 Black HPT 59 Shack Negative HD Pleural effusion Negative Probable Unknown 
20 Male 41 Black HPT 49 Brick Negative PD Pleural effusion Negative Probable Unknown 
 
Table 2 : Demographics and clinical characteristics of the patients who had TB. 
Abbreviations: CKD, chronic kidney disease; HPT, hypertension; GN, glomerulonephritis; INH, isoniazid; HD, haemodialysis; PD, peritoneal dialysis; MDR-
TB, multidrug resistant tuberculosis; TB, tuberculosis;,VUR, vesicoureteral reflux, AFB – Acid fast bacilli 
*Represents duration on dialysis before diagnosis with Tb 
**Represents drug sensitivity to first-line anti-tuberculous agents 
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The calculated incidence of TB in our unit was 4505 per 100 000 per year (see Figure 2 for a 
comparison to local incidence).   
 
 
Figure 2: Incidence of tuberculosis in the study population compared to the local, regional and 
national incidence in 2015
[12,13]
. 
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h. Discussion  
This single-centre retrospective cohort study reveals an extraordinarily high incidence of TB in 
dialysis patients in the Eastern Cape Province of South Africa, with a calculated incidence of TB 
4.1 times that of the local population and over 5 times that reported in the general population for 
the country as a whole.  This ratio is consistent with the previously reported results from other 
areas in the world
 [8]
.  The patients are predominantly young and HIV negative, reflecting the 
selection bias that exists within the South African public sector dialysis programme. Moosa et al 
have previously reported on rationing of dialysis treatment in South Africa and that patients are 
screened and accepted onto the dialysis programme based on favourable medical and 
socioeconomic criteria
[14]
. 
 
Several studies have shown that the risk of TB in dialysis patients is increased with incidence 
rates reported at 6.9-52.5 times higher than the general population 
[7, 8, 15]
. This observed increase 
in the incidence of TB in dialysis patients may be related to impaired cellular immunity in 
uraemic patients 
[3,16,17]
. Other factors which might contribute to the decreased immunity are 
malnutrition, vitamin D deficiency and hyperparathyroidism
 [18]
. 
 
Known TB risk factors assessed in this study  included age, employment status, smoking, alcohol 
use, average number of days admitted to hospital per year, housing type and TB contact status, 
HIV and Vitamin D levels
[19,20]
.  However, of all these risk factors, only informal housing and a 
history of hospitalization were significantly associated with a diagnosis of TB (p <0.05). In 
South Africa, informal housing (shack dwelling) is associated with overcrowding and unhygienic 
conditions which would favour the transmission of TB in the community.  While a history of 
hospitalization may represent a sicker cohort prone to TB, the lack of adequate isolation facilities 
in our hospital during the study period may well have contributed to nosocomial transmission of 
TB to our patients, although this is speculative.   Interestingly, HIV was not predictive of TB in 
our study, but this may be confounded by the low overall prevalence of HIV in our unit (11%).  
This low HIV prevalence reflects a selection bias for non-HIV positive patients in the public 
sector, despite a higher background HIV prevalence of 19.9% among the age group15-49 
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years
[20]
.  Moreover, all HIV positive patients on dialysis have undetectable viral loads and 
relatively preserved CD4 counts as per dialysis selection criteria in the public sector.  More 
patients with TB had a history of known contact (40% vs 25%), but this was not statistically 
significant (p= 0.174). The combined vitamin D deficiency/insufficiency prevalence for our 
cohort of patients was 45.7%.  Vitamin D deficiency was not shown to be a significant risk factor 
for the development of TB in this cohort. However, the vitamin D levels were not measured at 
the time of TB diagnosis since the assay has not always been available at our study centre.  
The incidence of extrapulmonary TB is very high at 30% in our study and is consistent with 
reports from previous studies of CKD patients 
[8,11,22-25]
. The increased tendency for extra 
pulmonary tuberculosis in chronic kidney disease is thought to be due to impaired cellular 
immunity
[24]
.  In dialysis patients, TB symptoms are often non-specific and difficult to 
distinguish from uraemic symptoms which can result in delayed diagnosis
 [8, 24]
. This may also 
facilitate transmission to other patients in the unit, particularly in haemodialysis units where 
patients spend much time in close proximity to each other.  Of the 20 TB cases, 7 (35%) were 
definite cases with positive microscopy or culture. Tamayo-Isla et al, in their retrospective TB 
peritonitis cohort study in South Africa, reported that mycobacterium tuberculosis was isolated 
in only 75% of their cohort
[9]
.  In our cohort, 13 of the 20 (65%) patients with TB were culture 
negative, reflecting the difficulty of definitive TB diagnosis in dialysis patients. 
Isoniazid (INH) chemoprophylaxis in HIV positive individuals has been found to be efficacious 
in a number of large scale randomized controlled trials with up to 74% reduction in TB incidence 
in select groups with a positive tuberculin skin test
[26]
.  Clear guidelines exist for the HIV 
positive population, but data on INH chemoprophylaxis in CKD patients is lacking. A few 
randomized clinical trials have assessed INH chemoprophylaxis in both pre and post-transplant 
patients and demonstrate benefit in administering chemoprophylaxis to transplant recipients for 
up to 1 year
 [27,28,29]
. Further large randomized clinical studies in the dialysis setting are required 
to help inform best practice on when to commence INH chemoprophylaxis and the most 
efficacious duration of therapy. 
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There were some limitations to the study. Due to the retrospective nature of the study, we were 
unable to include dialysis patients who had died during the study period, due to health record 
unavailability. Another limitation is that we cannot make assumptions about hospitalization as a 
risk factor for TB since we cannot prove causality, and details regarding the reason for 
admission, length of stay and timing in relation to onset of TB are not available. Strengths 
include the use of a single laboratory with standardized methodology as well as the availability 
of accurate clinical notes for determination of diagnosis.  While the overall numbers are 
relatively low for this cohort, a further strength is that the study included all patients alive on 
dialysis in the public sector for the entire Western part of the Eastern Cape and is therefore 
inclusive. 
i. Conclusion 
Dialysis patients in the Eastern Cape region of South Africa are at extremely high risk for the 
acquisition of tuberculosis, with a calculated incidence of 4505 per 100 000 population per year. 
There is a need for improved health care structures including the provision of adequate isolation 
facilities for patients with tuberculosis in our hospital and renal unit in order to reduce 
transmission. Further research on outcomes and response to TB treatment of CKD patients in 
South Africa is required.   Whether INH prophylaxis is a reasonable option for TB prevention in 
this population remains unknown and should be the subject of further study. 
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PART D: Supporting Documents   
a. Consent Form for Participation in a Research Study 
STUDY TITLE: The study of the burden of tuberculosis in patients with chronic kidney 
disease stage 5 who are undergoing renal replacement therapy with dialysis (CKD-5D) at 
Livingstone hospital renal unit in Port Elizabeth   
WHY IS THIS STUDY BEING DONE?  
You are invited to participate in a research study conducted by Dr Siviwe Ndamase. South Africa 
has a huge burden of tuberculosis and patients with chronic kidney disease are at increased risk 
of contracting tuberculosis compared to the general population. This study is done to determine 
burden of tuberculosis in dialysis patients at Livingstone hospital renal unit. 
Benefit of the study? 
The research will help inform us of the burden of tuberculosis in chronic kidney disease patients 
on dialysis at Livingstone hospital. With the information gained from this research we hope to 
make recommendations that will inform and ultimately improve the care of dialysis patients in 
the Eastern Cape. We also hope to identify modifiable risk factors that we can address. 
How and when will the study take place? 
Your participation will involve answering a few questions and will take approximately 5 
minutes. The questions will be answered in an interview format during one of your dialysis 
sessions. Questions will be explained in a language that is easy to understand for the interviewee. 
The interviewer is Xhosa and English speaking and will conduct the interview in Xhosa where 
required. 
Risks  
There are no known risks associated with this research.   
Informed consent and confidentiality 
Your names will not be recorded on the questionnaires and only the folder number will be used. 
The information obtained from the interviews will only be accessible to the individuals involved 
in the study. Your participation in this research study is voluntary. You may choose not to 
participate and you may withdraw your consent to participate at any time. You will not be 
penalized in any way should you decide not to participate or to withdraw from this study. Your 
HIV status will also be requested and the solely for the research purposes and will be kept 
completely confidential.
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Your privacy will be respected and only folder numbers and no patient names will be used. 
 
This consent form has been explained to me and I have been given the opportunity to ask questions. I fully understand the 
details and implications of the study and hereby give my consent to participate in this study. 
 
Participant’s signature_______________________________  Date:_________________ 
A copy of this consent form will be given to you. 
 
 
b. Data record form 
Data record form 
 
Demographics 
Case number  
Hospital number  
Consent signed  
Date of Birth:  
Age in years:  
47 
 
Race(self-reported) : lack        
Gender: Male     
Employment status: unemployed 
Smoking:  
 
current                         
If so: number of pack years 
Do you ever drink alcoholic beverages? 
 
  No 
If yes, what is your approximate intake of these beverages (units per 
week)? 
What type of house do you live in? Brick-house                                                shack 
How many people do you live with in the house?  
What fuel appliances do you use to cook at home: Electrical   gas    wood  
Dialysis history 
Dialysis day:  
Which year did you start dialysis  
Months on peritoneal dialysis:  
Months on haemodialysis  
Total months on any dialysis:  
Total months on any dialysis prior to TB diagnosis 
(where applicable) 
 
Date of dialysis cessation (where applicable) and why 
(example Tx/death etc) 
 
Date: 
Why? 
Have you been admitted to hospital between 1 April 
2010 and  31
st
 March 2014? 
 
Yes           No 
If yes number of days:____________________ 
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Tuberculosis history 
Did you get diagnosed TB between April 2010 and 
March 2014? 
            
If yes when----------------------------------- 
 
Is there anyone at home who has been diagnosed with 
tuberculosis? 
 
 
If yes, when? 
Details to get from file 
What type of TB were you diagnosed with extra-pulmonary 
How was the diagnosis made? mycobacterium TB identified on a clinical specimen either 
by culture or new molecular line probe assay specimen/acid fast 
bacilli) 
_______________________________________________________ 
 FB’S/TB culture negative for tuberculosis but patient 
with clinical features, histological and radiological abnormalities 
consistent with TB) 
:_______________________________________________________  
Drug sensitivity where known 
 
-  
Other medical history 
Have you been diagnosed with diabetes? 
 
 
 
Have you ever been on any immunosuppressive drugs 
e.g. prednisone, cyclosporine, azathioprine, and 
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cyclophosphamide: 
 
 
Primary diagnosis and cause of CKD if known     
 
1._________________________________________ 
2.__________________________________________ 
3.__________________________________________ 
 
Laboratory Results (Last Known Blood Results) 
Test Date 
Albumin  
 
Haemoglobin  
 
25,hydroxyVitamin D3  
 
 
HIV status  
 
Ferritin  
%transferrin sats  
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c. UCT ethics approval document
Signature removed  to avoid 
exposure online
51 
52 
d. Livingstone Hospital approval letter
signature removed to avoid 
exposure online
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e. Acceptance of abstract for moderated poster presentation at world congress 
of nephrology 2015 
 
 
 
  
                                                                                           Brussels, 28/11/2014 
  
Dear Dr Ndamase,   
  
Original Abstract Number:  WCN15-1194 
Abstract Title:  HIGH BURDEN OF TUBERCULOSIS IN SOUTH AFRICAN DIALYSIS PATIENTS: THE 
REPORT OF A SINGLE CENTRE IN THE EASTERN CAPE, SOUTH AFRICA. 
Number of your Poster Board: SUN-041   
Thank you for submitting your abstract(s) to the World Congress of Nephrology 2015. We are pleased to 
inform you that your abstract as listed above has been selected by the Scientific Program Committee for 
Moderated Poster Presentation at the Congress. 
Please find below important instructions for the preparation of your presentation at the congress. We 
recommend you to carefully read through all information provided. 
Registration 
To present your poster abstract, you must be registered to the Congress. WCN 2015 will provide Early 
Bird Registration for all poster presenters provided they register before 14 December 2014. If you are not 
yet registered, you can do so by simply clicking on the following link and follow the 
instructions.http://www.wcn2015.org/registration-home 
Kindly register using the same login details you have used for submitting your abstract, otherwise 
we will not be able to link your abstract to your registration. For your convenience find your logon 
details below: 
  
User name: Ndamase.Siviwe 
Password: 77225 
  
After completion of your registration you will receive a confirmation notification per email. Two weeks prior 
to the congress you will receive a personalized barcode letter, which you must bring with you to the 
Congress when picking up your badge and Congress material in the registration area.  If you applied for 
travel grant, please do not register before receiving your travel grant notification (by December 5, 2014). 
Accommodation 
After registering we remind you to also secure your accommodation in one of the designated Congress 
hotels. Note that demand on hotels in Cape Town is high so booking early is strongly advised. Bookings 
can be made through the official housing agency via http://www.wcn2015.org/accommodation . 
Poster Area 
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Posters will be located in the WCN 2015 Exhibition Hall situated on the ground floor of the Cape Town 
International Convention Centre (CTICC). 
Posters should be the following size: AO-size (1189 mm High x 841 mm Wide), portrait orientation. 
Important note: Larger posters in a different orientation will not fit on the poster boards. 
Your poster will be scheduled for presentation for one day only. Please see below for the scheduled day 
of your poster. The Exhibition Hall opens daily for poster presenters to mount their posters between 09.00 
am – 10.30am. Your poster must be removed between 03:40pm and 04:30pm latest. Posters that are not 
removed by 04:30pm will be removed by the organizers and can, unfortunately, not be recovered. 
  
Poster Presentation Date:                15/03/2015 
Number of your Poster Board:        SUN-041 
  
During the time of the moderated poster session you are expected to be physically present at your poster 
as it will be viewed and moderated. Please have your poster ready for viewing no later than 10:30am on 
the day of your presentation. The times of the moderated sessions are as follows: 
  
Saturday, 14 March                   11:00am – 12:00pm 
Sunday, 15 March                     11:00am – 12:30pm 
Monday, 16 March                    11:00am – 12:30pm 
  
Online ePoster Library 
In addition to your physical poster, the WCN 2015 will feature an online ePoster library. This library will be 
accessible onsite at electronic poster kiosks, as well as via the WCN web site during and for 12 months 
after the Congress. The library will allow all those who visit the congress to view your scientific 
work and interact with you through the email address displayed on the website and as such will increase 
the visibility of your scientific work. 
The WCN 2015 is grateful to Roche for its support in making the online ePoster library possible. 
Additional information on how to access the online ePoster Library, including login and customer service 
details will be provided separately after 8 January. For any queries about the online poster library, please 
contact societyposter@learnersdigest.com. 
Poster Printing Service 
The World Congress of Nephrology 2015 has selected Call4Posters® as their preferred poster printing 
service for WCN 2015. This service is the simple and most convenient way to print your poster and pick it 
up on-site at the congress in Cape Town. 
 
Additional information in this service will be sent after 8 January in a separate email. Please take note 
there will be no onsite poster printing service. For any queries about the online poster library, please 
contact societyposter@learnersdigest.com. 
We congratulate you again on having your abstract selected for presentation at the ISN World Congress 
of Nephrology 2015. We appreciate your participation and look forward to seeing you in Cape Town. 
Sincerely, 
  
  
Markus Ketteler                                             Mohammed Rafique Moosa 
WCN 2015 Abstract Co-Chair                       WCN 2015 Abstract Co-Chair 
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f. SAMJ Manuscript preparation guidelines 
 General article format/layout 
Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, which will delay publication.  
General: 
 Manuscripts must be written in UK English. 
 The manuscript must be in Microsoft Word format. Text must be single-spaced, in 12-
point Times New Roman font, and contain no unnecessary formatting (such as text in 
boxes). 
 Please make your article concise, even if it is below the word limit. 
 Qualifications, full affiliation (department, school/faculty, institution, city, country) and 
contact details of ALL authors must be provided in the manuscript and in the online 
submission process. 
 Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
 Include sections on Acknowledgements, Conflict of Interest, Author Contributions and 
Funding sources. If none is applicable, please state ‘none’.  
 Scientific measurements must be expressed in SI units except: blood pressure (mmHg) 
and haemoglobin (g/dL). 
 Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
 Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' but 
'50%' and '19ºC'. 
 Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not B 
for beta, etc. 
 Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
 Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
 Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
 If you wish material to be in a box, simply indicate this in the text. You may use the table 
format –this is the only exception. Please DO NOT use fill, format lines and so on. 
  
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
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- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, although 
they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ can be 
glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
 Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
 HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
 OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
 Bennet et al. Standardized human pedigree nomenclature: Update and assessment of the 
recommendations of the National Society of Genetic Counselors. J Genet Counsel 
2008;17:424-433: standard human pedigree nomenclature. 
 
Research 
Guideline word limit: 4 000 words 
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, results, 
discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that clearly 
lay out the rationale for conducting the study. Some common reasons for conducting a study 
are: to fill a gap in the literature, a logical extension of previous work, or to answer an 
important clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods in as 
much detail as possible so that others would be able to replicate the study should they need to. 
Results should describe the study sample as well as the findings from the study itself, but all 
interpretation of findings must be kept in the discussion section, which should consider primary 
outcomes first before any secondary or tertiary findings or post-hoc analyses. The conclusion 
should briefly summarise the main message of the paper and provide recommendations for 
further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text . 
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Structured abstract 
 This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published 
work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the 
intervention, primary and secondary outcomes, any specific analyses that were 
done on the data. 
o Results: first sentence must be brief population and sample description; outline 
the results according to the methods described. Primary outcomes must be 
described first, even if they are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
 Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
 Do not include any references in the abstracts. 
 Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
 Objectives (within Introduction/Background): a clear statement of the main aim of the 
study and the major hypothesis tested or research question posed 
 Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
 Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
 Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural 
factors (e.g. smoking status, socioeconomic group, educational attainment, co-existing 
disease indicators, etc)that may have an impact on the study results. Clearly define how 
participants were enrolled, and describe selection and exclusion criteria. 
 Interventions (within Methods): what, how, when and for how long. Typically for 
randomised controlled trials, crossover trials, and before and after studies. 
 Main outcome measures (within Methods): those as planned in the protocol, and those 
ultimately measured. Explain differences, if any. 
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Results 
 Start with description of the population and sample. Include key characteristics of 
comparison groups. 
 Main results with (for quantitative studies) 95% confidence intervals and, where 
appropriate, the exact level of statistical significance and the number need to treat/harm. 
Whenever possible, state absolute rather than relative risks. 
 Do not replicate data in tables and in text. 
 If presenting mean and standard deviations, specify this clearly. Our house style is to 
present this as follows: 
 E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean 
(SD). 
 Leave interpretation to the Discussion section. The Results section should just report the 
findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings are 
not needed: 
 Statement of principal findings 
 Strengths and weaknesses of the study 
 Contribution to the body of knowledge 
 Strengths and weaknesses in relation to other studies 
 The meaning of the study – e.g. what this study means to clinicians and policymakers 
 Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do not 
go beyond the data in the article. 
  
Illustrations/photos/scans 
 If illustrations submitted have been published elsewhere, the author(s) should provide consent to 
republication obtained from the copyright holder. 
 Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
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 Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
 All images must be of high enough resolution/quality for print. 
 All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
 Ensure all graph axes are labelled appropriately, with a heading/description and units (as 
necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 etc. 
 Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of a low 
malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow to show 
the tumour. 
 Each image must be attached individually as a 'supplementary file' upon submission (not solely 
embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc. 
  
Tables 
 Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
 Large tables will generally not be accepted for publication in their entirety. Please consider 
shortening and using the text to highlight specific important sections, or offer a large table as an 
addendum to the publication, but available in full on request from the author 
 Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
 Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively in the 
text. 
 Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
 Ensure each table has a concise title and column headings, and include units where necessary. 
 Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || then ** 
†† ‡‡ etc. 
  
Do not: Use [Enter] within a row to make ‘new rows’: 
  
Rather: 
Each row of data must have its own proper row: 
Do not: use separate columns for n and %: 
Rather: 
Combine into one column, n (%): 
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Do not: have overlapping categories, e.g.: 
  
Rather: 
Use <> symbols or numbers that don’t overlap: 
  
  
References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
 Authors must verify references from original sources. 
 Citations should be inserted in the text as superscript numbers between square brackets, e.g. 
These regulations are endorsed by the World Health Organization,
[2]
 and others.
[3,4-6]
 
 All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). 
 Approved abbreviations of journal titles must be used; see the List of Journals in Index Medicus. 
 Names and initials of all authors should be given; if there are more than six authors, the first 
three names should be given followed by et al. 
 Volume and issue numbers should be given. 
 First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
 Wherever possible, references must be accompanied by a digital object identifier (DOI) link). 
Authors are encouraged to use the DOI lookup service offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
From submission to acceptance 
Submission and peer-review 
To submit an article: 
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 Please ensure that you have prepared your manuscript in line with the SAMJ requirements. 
 All submissions should be submitted via Editorial Manager 
 The following are required for your submission to be complete: 
o Anonymous manuscript (unless otherwise stated) 
o Author Agreement form 
o Manuscript 
o Any supplementary files: figures, datasets, patient consent form, permissions for published 
images, etc. 
 Once the submission has been successfully processed on Editorial Manager, it will undergo a 
technical check by the Editorial Office before it will be assigned to an editor who will handle the 
review process. If the author guidelines have not been appropriately followed, the manuscript 
may be sent back to the author for correcting. 
 
 Sponsored supplements 
Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that do 
not adhere to these guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set out 
by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word document format. The text is single-spaced, in 12-
point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (PDF or jpeg). These must be submitted individually as 'supplementary files' (not 
solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
